| Literature DB >> 34281165 |
Ilse Van Gucht1, Alice Krebsova2, Birgitte Rode Diness3, Steven Laga4, Dave Adlam5, Marlies Kempers6, Nilesh J Samani5, Tom R Webb5, Ania A Baranowska5, Lotte Van Den Heuvel1, Melanie Perik1, Ilse Luyckx1, Nils Peeters1, Pavel Votypka7, Milan Macek7, Josephina Meester1, Lut Van Laer1, Aline Verstraeten1, Bart L Loeys1,6.
Abstract
Thoracic aortic aneurysm and dissection (TAAD) is a major cause of cardiovascular morbidity and mortality. Loss-of-function variants in LOX, encoding the extracellular matrix crosslinking enzyme lysyl oxidase, have been reported to cause familial TAAD. Using a next-generation TAAD gene panel, we identified five additional probands carrying LOX variants, including two missense variants affecting highly conserved amino acids in the LOX catalytic domain and three truncating variants. Connective tissue manifestations are apparent in a substantial fraction of the variant carriers. Some LOX variant carriers presented with TAAD early in life, while others had normal aortic diameters at an advanced age. Finally, we identified the first patient with spontaneous coronary artery dissection carrying a LOX variant. In conclusion, our data demonstrate that loss-of-function LOX variants cause a spectrum of aortic and arterial aneurysmal disease, often combined with connective tissue findings.Entities:
Keywords: ECM; LDS; LOX; MFS; TAAD
Mesh:
Substances:
Year: 2021 PMID: 34281165 PMCID: PMC8269155 DOI: 10.3390/ijms22137111
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1(A) Overview LOX protein and location of variants found in five new probands and literature. Variants leading to premature stop codons and missense variants are highlighted in, respectively, green and purple [4,5,6,7]. (B) Conservation of affected LOX amino acids.
Figure 2Pedigrees of LOX families. The probands are indicated with an arrow. Black symbols indicate family members that are affected with aortic/arterial aneurysm/dissection. Deceased individuals are indicated with a diagonal line. Plus and minus signs are used to indicate the presence and absence of the respective LOX variant.
Figure 3Representative pictures of collagen and elastin stainings performed in a control and two LOX patients, respectively, patient 1-III:4 and 1-III:6. The scale bar represents 100 μm.
Figure 4Pictures of immunohistochemistry stainings of pSMAD2 and pERK1/2 in a control and two LOX patients, respectively, 1-III:4 and 1-III:6. Black arrows indicate examples of positive stained nuclei. The scale bar represents 50 μm.
Summary of clinical findings of our cohort of patients with LOX variants compared to literature.
| Characteristics | Literature [ | Our Cohort |
|---|---|---|
| Total number of patients | ||
| Male/female | 20/8 (1 unknown) | 13/3 |
| Age range at diagnosis | 11–73 years (median 46 years) | 6–55 years (median 45 years) |
| Thoracic aortic dissections | ||
| Elective surgeries | ||
| BAV | ||
| Disease beyond ascending aorta | Aneurysm in brachiocephalicus, arteria hepatica, abdominal aorta | Coronary artery dissection |
| Connective tissue findings |